REAL ENDPOINTS - Key Persons

Job Titles:

• Observer

Art has over 40 years of experience as a pharmaceutical industry executive and venture capital investor in life science companies. Art founded Pappas Capital in 1994, and over the past twenty-seven years the firm has managed more than $540 million in capital and invested in more than 85 companies. Art currently serves as a director for Sorriso Pharmaceuticals and OrphoMed, and as a board observer for Real Endpoints. Prior to founding Pappas Capital, Art held senior leadership positions at Glaxo Holdings, Abbott International, Merrell Dow Pharmaceuticals and the Dow Chemical Company. He previously served as Chairman for CoLucid Pharmaceuticals, as a director for Aura Biosciences, Reneo Pharmaceuticals, Afferent Pharmaceuticals, Arix Bioscience, Chimerix, TYRX, Quintiles Transnational Corp., Syntonix Pharmaceuticals, LEAD Therapeutics and Embrex; and as a board observer for Amplyx Pharmaceuticals, Balance Therapeutics, Kezar Life Sciences, Milestone Pharmaceuticals and Plexxikon. Art holds various director, trustee and advisor positions for the North Carolina Biotechnology Center, the Medical University of South Carolina Foundation for Research Development, The Wistar Institute, the Ronald McDonald House of Durham & Wake, the Duke Cancer Institute, and the BioExec Institute. Art is a decorated Vietnam veteran, having served as an officer in the US Army 101st Airborne Division and with 2nd PSYOP Airborne JFK Special Warfare. Art received a BS in biology from The Ohio State University and an MBA in finance from Xavier University.

Job Titles:

• Founder
• Member of the Board
• Senior Advisor

Dennis is the Founder, Senior Advisor, and previous Senior Managing Partner of Aisling Capital LLC., a leading investment firm that invests in products, technologies, and global businesses across the Life Sciences industry. Aisling Capital has raised over $1.8 billion since inception. Prior to founding Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase Hambrecht & Quist, where he supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries. Previously, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc. Dennis is a frequent commentator on the industry and is actively involved with many of the industry's professional organizations. He has been a member of the board of numerous private and public healthcare companies and currently serves as Executive Chairman of Poliwogg Holdings. He sits on the board of Summus Global, Inc., Life Science Leader Magazine -Editorial Advisory Board, NY BIO Association, and the NY Investment Fund, as well as a Senior Industry Advisor for Bioscience Managers Pty Ltd. Mr. Purcell is a member of The University of Delaware Investment Committee, Harvard Kennedy School - M-R CBG Advisory Council, and the New York Leadership Council. He received his MBA from Harvard University and his BS in Accounting from the University of Delaware.

Job Titles:

• Member of the Board
• Chief Medical Officer and Senior Vice President for Harvard Pilgrim Health Care

Dr. Michael Sherman serves as Chief Medical Officer and senior vice president for Harvard Pilgrim Health Care. He also serves on the faculty of Harvard Medical School's Department of Population Medicine, as Chair of the Board of Managers of the Harvard Pilgrim Health Care Institute and on the Advisory Board of the Institute for Clinical and Economic Review (ICER). Dr. Sherman also is the current Chair for AHIP's CMO Leadership Council, comprised of chief medical officers from health plans throughout the United States. Prior to joining Harvard Pilgrim, Dr. Sherman held leadership roles at Humana, UnitedHealth Group, and Thomson Medstat. He practiced as a cardiac anesthesiologist prior to pursuing his MBA. He is a diplomate of the American Board of Anesthesiology and American Board of Medical Management, and a fellow of the American College of Physician Executives. Dr. Sherman is a frequent speaker at conferences and has lectured as part of the Harvard Business School executive education program. He currently serves on the board of directors and as co-president of the Harvard Business School Healthcare Alumni Association, the board of advisors for the Harvard Business School Healthcare Initiative, the board of directors for the Personalized Medicine Coalition, and board of overseers for Boston's Museum of Science. He holds a BA and an MS in Biomedical Anthropology from the University of Pennsylvania and received his MD from Yale and MBA from the Harvard Business School.

Job Titles:

• Leader
• Member of the Board
• Chief Executive Officer of Equity Healthcare

Dr. Robert Galvin is the Chief Executive Officer of Equity Healthcare (EH), which oversees the management of health care for firms owned by private equity companies. EH encompasses 50 companies with health care spending exceeding $1.5 billion annually, and is a wholly owned subsidiary of Blackstone, where Dr. Galvin is an Operating Partner. Previously, Dr. Galvin was Executive Director of Health Services and Chief Medical Officer for General Electric for 15 years, where he was in charge of the design and financial and clinical performance of GE's health programs globally. Dr. Galvin is a nationally recognized leader in the areas of market-based health policy and financing, quality measurement, and payment reform. His work has been widely published in many esteemed medical journals and reviews. Dr. Galvin was a founder of two groups: Bridges to Excellence/PROMETHEUS Payment, and Catalyst for Payment Reform (CPR), innovative endeavors that have helped drive the quality agenda. He is also Chairman of the Board of CPR. Dr. Galvin is a member of the Institute of Medicine, and a Professor Adjunct of Medicine and Health Policy at Yale University. He has received awards for his work from the National Business Group on Health, Healthcare Financial Management Association, and National Coalition for Cancer Survivorship. He is a fellow of the American College of Physicians. Dr. Galvin holds a BA and MD from the University of Pennsylvania and an MBA from Boston University.

Job Titles:

• Member of the Senior Leadership Team
• Vice President, Consulting Services & Communications

Job Titles:

• Chief Clinical Officer
• EVP
• Member of the Senior Leadership Team
• Clinical and Strategic Executive
• Senior Advisor to the MIT Center for Biomedical Innovation New Drug Development Paradigms Initiative

Dr. Jane Barlow is a clinical and strategic executive with over 25 years of healthcare leadership experience. She is EVP and Chief Clinical Officer for Real Endpoints, where she focuses on evaluating the economic impact and value of pharmaceuticals and diagnostics to aid in defining access, coverage, and contracting strategies with a focus on outcomes. Dr. Barlow is Senior Advisor to the MIT Center for Biomedical Innovation New Drug Development Paradigms Initiative project on Financing of Curative Therapies in the US (FoCUS). As part of this initiative, she leverages her deep payer expertise to evaluate the impact of durable cell and gene therapies on payer financing and reimbursement strategies. The MIT NEWDIGS consortium FoCUS Project seeks to understand the financial challenges durable cell and gene therapies may create and generates solutions to promote sustainable patient access. This multi-stakeholder effort gathers input from over 150 individuals from over 50 organizations including patient advocacy groups, payers from all segments of the US healthcare system, manufacturers, ALKs, regulators, and academics working in healthcare policy, financing, and reimbursement. Before joining RE, Dr. Barlow served as Associate Chief Medical Officer for CVS Health where she drove clinical strategies supporting drug purchasing, distribution, and utilization management for over 5B prescriptions yearly including over $40B in specialty revenue. In addition, she was Chief Medical Officer for the 11M life Medicare and government services business segment and served on the Board of Directors for SilverScript Insurance Company. Dr. Barlow has also held leadership roles Medco Health Solutions, IBM, the U.S. military, federal government, industry, and private practice. Dr. Barlow attended medical school at Creighton University and completed her residency training in occupational medicine at Johns Hopkins University. She holds masters' degrees in business administration and public health and is a Certified Physician Executive with a certificate in Health Information Technology from the American Association of Physician Leaders. Dr. Barlow is board-certified in occupational medicine and is a fellow of both the American College of Occupational and Environmental Medicine and the American College of Preventive Medicine. She serves on the board of directors of Momenta Pharmaceuticals, Inc. and the advisory board for Pictet Asset Management. She previously served on the board of TherapeuticsMD.

Job Titles:

• CEO
• Director
• Member of the Board
• Member of the Senior Leadership Team

Mr. Berkowitz is one of the rare top executives whose career has spanned most key verticals in global healthcare - with executive committee and other senior roles at United Health Group, Walgreens Boots Alliance (formerly Walgreens), Merck and Schering-Plough. He joined RE from UnitedHealth Group/Optum where he led Optum's International division as CEO while also driving key strategic initiatives within Optum's pharmacy benefits management division. Prior to joining United, Mr. Berkowitz served as President of Pharma and Global Market Access at the Walgreens Boots Alliance, responsible for generic and branded procurement, inventory management, relationships with pharmaceutical companies as well as the companies pricing and reimbursement strategies with all payors and payor segments. Mr. Berkowitz also had responsibility for the specialty pharmacy business with over $10 billion in revenue and 5,800 employees. Mr. Berkowitz joined Walgreens from Merck & Co., where, as SVP of global market access, he was accountable for all access, pricing, payer marketing, health outcomes and health technology assessments worldwide. Mr. Berkowitz had held a similar position at Schering-Plough, where he started as legal director for Schering-Plough's managed care and commercial group in 1998. Before joining Schering, Mr. Berkowitz was a healthcare attorney for the international law firm Proskauer LLP in New York and Washington, D.C. Mr. Berkowitz earned his bachelor's degree in political science from Union College in Schenectady, N.Y., and his Juris Doctor from Brooklyn Law School in Brooklyn, N.Y. He has been recognized three times in PharmaVoice magazine as one of the 100 Most Inspiring Leaders in the Life Sciences in 2009, 2010 and 2012 and is the recipient of PharmaVoice's inaugural Red Jacket recognition. Mr. Berkowitz serves on the board of directors of H. Lundbeck A/S, Esperion Therapeutics, Inc., and Zealand Pharmaceuticals, Inc. Berkowitz also serves as an Editorial Advisor to Life Science Leader and Pharmaceutical Commerce magazines and served on the Board of Directors of the Swiss-American Chamber of Commerce.

Job Titles:

• Member of the Senior Leadership Team
• Vice President, Patient Services & Client Development
• Vice President, Patient Services and Business Development

Job Titles:

• Member of the Board

Linda has been serving as the President of Pharma Intelligence at Informa since May 2015, overseeing an income statement of just over $100 million, returning the business to a growth of 1% in 2015 and 4.3% in 2016. During that timeframe, the division restructured an organization of 400 employees into one business, successfully launched 2 new products, won several Informa awards, and delivered 3 large development investments totaling $12 million focusing on material product enhancements. Prior to her current role, she served as President of Citeline (an Informa company) from 2010 to 2015 driving a compound annual growth rate of 7.25%. She originally came to Citeline as Director of Sales in 2004 to launch its flagship product, Trialtrove. Under her tenure Citeline acquired all of the top 20 pharmaceutical companies worldwide as clients, successfully launched four new products, and won several Informa awards. Linda came to Citeline with extensive sales and sales management experience in the pharmaceutical industry with Decision Resources, Johnson & Johnson, and Bristol-Meyers Squibb. Prior to her sales experience, Linda was a Certified Public Accountant with KPMG, and a Senior Vice President with Fourth Financial, a US Bank Holding Company. Linda received her BS with majors in business administration and accounting from the University of Kansas.

Job Titles:

• Director of Patient Access Services & Analytics
• Director, PAS and Analytics

Matt Dionne serves as the Director of Patient Access Services & Analytics at Real Endpoints. Matt oversees analytics for Patient Access Services initiatives, leads RE technology activities, and provides reimbursement and access expertise for clients in patient support functions. Prior to joining Real Endpoints, Matt was an award-winning manager at Celgene with experience in driving patient engagement and customer satisfaction, adept at transforming complex data into real world solutions. For 7 years in Patient Support Services, he utilized an agile approach to adapt and launch several pharmaceutical and medical benefit drugs in Celgene's Hematology / Oncology portfolio. He also was responsible for digital and data driven initiatives, notably establishing Celgene's first cloud-based CRM (customer relationship management) solution. As a leader of a regional team of Patient Support Specialists, Matt provided reimbursement and access support to key centers of excellence. He served as a reimbursement and access resource to other departments within Celgene by utilizing payer knowledge to provide overviews of reimbursement insights, proactively identify new reimbursement hurdles, and collaborate on potential solutions. Before Celgene, Matt worked as a Pharmacy Services Representative for CVS / Caremark Specialty Pharmacy. In this capacity he developed relationships nationwide with customers, physicians, & insurance companies to ensure timely completion of orders regarding dealing with exceptions in enrollment, coverage, & prescription refills. He also spent 6 years as a certified pharmacy technician at Walgreens Pharmacy (retail). Matt leverages his 15 years of patient-facing reimbursement experience to develop patient-centric approaches to business problems facing clients today ranging from access issues to engaging the patient where they are using technology.

Job Titles:

• Vice Chairman
• Vice Chairman of the Board

Norman C. Selby has spent over 35 years in the healthcare world in a variety of consulting, managerial, investor and Board roles. His current focus is on Real Endpoints llc, an information and analytics company focused on pharmaceutical pricing, reimbursement and market access which he co-founded, as well as several healthcare IT start-ups. He is also Lead Director of Infinity Pharmaceuticals (INFI), a public biotech oncology company. Among earlier roles Norman was co-Founder and initial Chairman of Paige.AI, CEO of TransForm Pharmaceuticals, Founder and Executive Chairman of Physicians Interactive Holdings, Executive Chairman of Windhover Information, and Board member of Millennium Pharmaceuticals (MLNM). Mr. Selby spent the first half of his career at McKinsey & Company where he was Director and Senior Partner in the firm's New York office, and head of the firm's Global Pharmaceuticals and Medical Products Practice. From 1987-1989, Mr. Selby took a leave of absence from McKinsey to serve as Chief Operating Officer of the New York Blood Center, the largest community blood organization in the country, where he led its financial and operational turnaround. Mr. Selby serves on the Board of Trustees of the Central Park Conservancy and the Memorial Sloan-Kettering Cancer Center, and is a member of the Council on Foreign Relations, all based in New York City. He is also on the Advisory Board of the Harvard Business School's Healthcare Initiative. Mr. Selby holds a BA in Architecture from Yale College and an MBA with Distinction from the Harvard Graduate School of Business Administration.

Job Titles:

• Member of the Senior Leadership Team
• RE 's VP Specialty
• Senior Vice President, Specialty
• Vice President, Specialty

Rob O'Brien, RE's VP Specialty, has over 20 years of managed care, PBM, and specialty pharmacy experience. Over the past 2 decades at CVS Health, he has worked closely with payers across all business segments (commercial and government) and drug benefit programs (both pharmacy and medical). At CVS Health he held a number of leadership positions of increasing responsibility. He directed the Health Plan segment clinical team for 8 years, then moved to CVS Specialty where he led a team of specialty clinical experts supporting PBM customers on managing specialty trend and patient care as well as a product development and innovation team that brought to market CVS Specialty's innovative digital engagement tools for its specialty patients. During his tenure, the business grew to over $60 billion, serving over a million patients a year. While at CVS Health, Rob also had accountability for leading the sales efforts for medical benefit management solutions and commercialization of the PBM product portfolio. Under Rob's leadership, CVS' Novologix hit record sales and adoption of Novologix's medical benefit management solution, while also continuing to expand Novologix's capabilities across integrated benefit prior authorization, oncology management, medical rebates, and site of care optimization. Rob attended Albany College of Pharmacy and is a licensed pharmacist located in New York.

Job Titles:

• Chairman
• Founder
• Member of the Board
• Member of the Senior Leadership Team
• Co - Founder and Chairman of Real Endpoints LLC

Roger Longman is co-founder and chairman of Real Endpoints LLC, a leading reimbursement-focused analytics and advisory firm. Roger is recognized as an expert in biopharmaceutical strategy and reimbursement and often speaks at key industry events organized by important trade organizations, investment banks, venture capital firms, and leading biopharma companies. He has been involved with the health-care industry for more than 30 years. At his first venture, the co-founding of Windhover Information, he and his team created a number of industry-standard analytical sources, including must-read strategy publications such as IN VIVO and Start-Up, the strategic transactions database and a major conference business for senior executives. The business was acquired by Elsevier where for two years Longman ran the company's pharmaceutical business information group. Roger co-founded Real Endpoints in 2011. Since then, RE has developed a number of value-based approaches to developing and commercializing drugs and diagnostics - including proprietary tools for objective analysis of drug value; innovative contracting structures and processes for negotiating, monitoring, and reconciling the agreements; the RE Marketplace platform; and objective assessments of, and development of strategies for, patient- and provider-support services, including a new patient-support database focusing on Medicare patients, RE Assist. He lectures regularly at several leading universities and co-directed the Wharton-Windhover pharmaceutical program at The Wharton School of the University of Pennsylvania. Mr. Longman completed his BA at Cornell University and MA in English Literature at the University of North Carolina at Chapel Hill, then taught for three years at the European division of the University of Maryland.

Job Titles:

• Member of the Senior Leadership Team
• Vice President, Client Services
• Senior Vice President, Client Services
• Vice President for Client Services

Ryan Walsh serves as the Vice President for Client Services at Real Endpoints. In this capacity, Ryan is responsible for marketing and promotional activities, product, and service quality and, most importantly, client development and support. Ryan joins Real Endpoints from Novartis where he was a leader in the market access organization with responsibility for access strategy development and execution for the immunology portfolio. Prior to Novartis, served as an executive at Walgreens, where he led the development and implementation of a portfolio of innovative, multichannel solutions to provide value to global biopharmaceutical manufacturers in the areas of commercial strategy and patient acquisition and retention. With over 20 years of pharmaceutical and trade industry experience, Ryan has developed strong expertise in a wide variety of areas, including, business strategy, market access strategy and marketing, pricing and contracting, operations and clinical training through a variety of roles at Walgreens, Merck and Schering-Plough.

Job Titles:

• Member of the Senior Leadership Team
• President

Susan Raiola is the President of Real Endpoints. Ms. Raiola has over 15 years of experience in the pharmaceutical consulting industry with a primary emphasis on reimbursement and market access. Ms. Raiola has consulted for both large and small pharmaceutical companies and has assisted with the commercial strategy for both new and inline products. Her experience ranges across multiple therapeutic areas including immunology, gastroenterology, cardiovascular, oncology (both solid and liquid), as well as orphan diseases. Ms. Raiola has developed several novel diagnostic assessments including Hub Excellence™, which optimizes the design of patient support programs based on competitor benchmarking, key stakeholder insights, and assessments of customer unmet needs & pain points. In addition, she has developed RE Assist, an online tool that helps Medicare patients navigate financial hurdles. Through both of these tools, Ms. Raiola and her team provide actionable insights and develop a tactical roadmap to maximize customers' market access opportunities. Ms. Raiola began her career as a financial analyst for Prudential, eventually managing a division responsible for individual insurance financial analysis and projections. She holds a BS in Finance, summa cum laude, from Seton Hall University. In 2019 she was recognized in PharmaVoice magazine as one of the 100 Most Inspiring Leaders in the Life Sciences.